[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624045":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":45,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Institute of Oncology Ljubljana","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Patients receive induction chemotherapy followed by chemoradiotherapy with cetuximab.",[13],"Drug: Cetuximab (CRC)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cetuximab (CRC)","Cetuximab is administered in combination with induction chemotherapy followed by concurrent chemoradiotherapy, according to the study protocol.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Klavdija Korošec","CONTACT","+386 31630065","kkorosec@onko-i.si",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Neža Gros","ngros@onko-i.si",[31],{"facility":5,"status":32,"city":33,"state":20,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Ljubljana","1000","Slovenia",{"type":37,"coordinates":38},"Point",[39,40],14.50513,46.05108,{"lat":40,"lon":39},[43,44],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100624045",false,"NCT07404527","Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery","Usefulness of Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation and Complication Prediction in Oncological Patients Undergoing Colorectal Surgery","Inclusion Criteria:\n\nAdult patients (≥18 years of age).\n\nHistologically confirmed head and neck cancer.\n\nIndication for induction chemotherapy followed by chemoradiotherapy with cetuximab.\n\nAdequate organ function as required by the study protocol.\n\nAbility to provide informed consent.\n\nExclusion Criteria:\n\n* Prior systemic therapy or radiotherapy for head and neck cancer.\n\nPresence of uncontrolled comorbidities that would preclude study treatment.\n\nKnown hypersensitivity to cetuximab or components of the treatment regimen.\n\nPregnancy or breastfeeding.","ALL","18 Years",{"count":56,"type":57},60,"ESTIMATED","INTERVENTIONAL",[60],"NA","Sarcopenia is a complex syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength. In patients with cancer, sarcopenia is associated with poorer prognosis, increased treatment-related toxicity, higher postoperative complication rates, reduced response to therapy, and decreased quality of life. Importantly, sarcopenia may be present even in patients with preserved nutritional status or overweight.\n\nPatients with gastrointestinal cancers are at particularly high risk of developing sarcopenia, both as a consequence of the malignant disease itself and as a result of systemic anticancer treatment. Early identification of patients at risk is therefore essential in order to enable timely nutritional and supportive interventions.\n\nThe aim of this study is to evaluate the proportion of patients with gastrointestinal cancer who screen positive for sarcopenia risk using the SARC-F questionnaire before the start of systemic treatment and during treatment. Patients with a positive screening result will be referred for further clinical nutritional assessment and managed according to a multidisciplinary approach.",[63,64],"Gastrointestinal Cancer","Digestive System Neoplasms",[66],"SARC-F","2026-02-11",{"date":69,"type":70},"2026-02-13","ACTUAL",{"date":72,"type":70},"2023-10-24",{"date":74,"type":57},"2026-03-31",{"name":5,"class":6},1]